Imlifidase (2) – Idefirix®
Desensitisation in kidney transplantation
Characteristics
| Start date | 15.10.2026 |
|---|---|
| Resolution | 15.04.2027 – active procedure |
| INN | Imlifidase |
| Brand name | Idefirix® |
| Pharm. company | Hansa Biopharma AB |
| G-BA Procedure ID | D-1388 |
| Therapeutic area | Genitourinary system diseases Orphan |
| Reason for procedure | Reassessment: G-BA limitation |
Associated procedures
| Imlifidase (2) | Idefirix® | Hansa Biopharma AB | Desensitisation in kidney transplantation | n.d. | active procedure Orphan | |
| Imlifidase (1) | Idefirix® | Hansa Biopharma AB | Desensitisation in kidney transplantation |
0
3–69 |
100% Hint for non-quantifiable additional benefit Orphan repealed |
<< List of all resolutions